Compare Vanguard Tax Managed Fund FTSE Developed Markets ETF (VEA) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Tax Managed Fund FTSE Developed Markets ETF vs GeneDx Holdings Corp — how do they compare? Vanguard Tax Managed Fund FTSE Developed Markets ETF trades at $70.12 (market cap $323.80B), while GeneDx Holdings Corp trades at $68.18 (market cap $2.02B). The key difference: Vanguard Tax Managed Fund FTSE Developed Markets ETF is far larger — about 160.3× GeneDx Holdings Corp's market cap, and Vanguard Tax Managed Fund FTSE Developed Markets ETF is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Vanguard Tax Managed Fund FTSE Developed Markets ETF for 131 Days and GeneDx Holdings Corp for 19 Days on average.
| VEA | WGS | |
|---|---|---|
Market Cap | $323.80B | $2.02B |
Volume | 17,001,112 | 734,640 |
52-Week High | $73.79 | $167.51 |
52-Week Low | $58.90 | $34.51 |
Typical Hold Time | 131 Days | 19 Days |
Sector | — | Health |
Enterprise Value | — | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VEA trades at $70.19, down 0.1% with a bearish technical signal. The ETF shows mixed institutional activity with some firms increasing positions while others reduced holdings. Recent news highlights VEA's competitive advantages including a low 0.03% expense ratio and higher dividend yield compared to peers. Technical indicators show oversold conditions with RSI at 28.4, suggesting potential for near-term bounce.
The outlook remains cautious given bearish technical momentum, though the fund's cost efficiency and developed market exposure provide long-term value. Key risks include global market volatility and currency fluctuations. Investors should monitor institutional flow trends and global economic developments for directional cues.
GeneDx (WGS) trades at $68.50, down 0.04% with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue of $114.4M beating expectations but net income margin remains negative at -23.4%. Recent developments include new product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus targets $81.00 (18% upside), fundamental challenges persist with negative profitability metrics and high valuation multiples. The stock faces execution risks amid competitive genomics landscape, but operational improvements and testing volume growth provide potential catalysts for recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Vanguard Tax Managed Fund FTSE Developed Markets ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Developed All Cap ex US Index, a market-capitalization-weighted index that is made up of approximately 4022 common stocks of large-, mid-, and small-cap companies located in Canada and the major markets of Europe and the Pacific region. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VEA →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
